Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Genome Editing Market size & share revenue was valued at approximately USD 11.2 Billio…
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $2.21 per share a year ago. These figures are adjusted for non-recurring item…
Here are the major earnings before the open Tuesday
Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * PayPal Holdings (PYPL [https://seekingalpha.com/symbol/PYPL]) * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET])…
Precision BioSciences Q1 2026 Earnings Preview
* Precision BioSciences (DTIL [https://seekingalpha.com/symbol/DTIL]) is scheduled to announce Q1 earnings results on Tuesday, May 5th, before market open. * The consensus EPS Estimate is -$0.81 [https://seekingalpha.com/symbol/DTIL/earnin…
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio
In early March 2026, Precision BioSciences announced it hit a clinical milestone under its license with TG Therapeutics for azercabtagene zapreleucel in progressive multiple sclerosis, triggering a US$7.5 million payment that combines US$5…
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. TG Therapeutics and Precision BioSciences reached a clinical milestone for azercabtagene zapreleuce…
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock– – Cash received supports Precision’s expected cash runway through 2028 and strategic focus on in vivo gene editing pipeline – DURHAM, N.C., Marc…
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.96 per share a year ago. These figures are adjusted for non-recurring items.…
Sidoti Events, LLC's Year-End Virtual Investor Conference
NEW YORK, NY / ACCESS Newswire / December 9, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day Year-End Virtual Investor Conference taking place Wednesday…
Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb
(RTTNews) - Several small-cap biotech and healthcare stocks posted notable gains in after-hours trading on Friday, November 28, 2025, despite limited fresh news flow. Below is a roundup of the key movers. BioAtla Inc. (BCAB) shares surged…
Precision BioSciences launches $75M stock and warrant offering
* Precision BioSciences (DTIL [https://seekingalpha.com/symbol/DTIL]) on Monday reported [https://seekingalpha.com/pr/20301602-precision-biosciences-announces-75-million-offering-of-common-stock-pre-funded-warrants-and]an underwritten offe…
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * ConocoPhillips (COP [https://seekingalpha.com/symbol…
Precision BioSciences Q2 2025 Earnings Preview
* Precision BioSciences (NASDAQ:DTIL [https://seekingalpha.com/symbol/DTIL]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. * The consensus EPS Estimate is -$2.21 [https://seekingalpha.com/symbol/…
Qiagen (QGEN) Matches Q2 Earnings Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.6 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.57 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it wa…
Precision BioSciences: FDA Grants Orphan Drug Designation For PBGENE-DMD
(RTTNews) - Precision BioSciences (DTIL) announced the FDA has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy. PBGENE-DMD was recently granted FDA Rare Pediatric Disease designation for the…
Precision BioSciences reports promising DMD gene editing results
DURHAM, N.C. - Precision BioSciences (NASDAQ:DTIL), a small-cap biotechnology company currently valued at $49.34 million, announced new preclinical data for its PBGENE-DMD gene editing candidate for Duchenne muscular dystrophy (DMD) showin…
Precision Biosciences director Brown buys $6963 in DTIL stock
Director Melinda Brown of Precision Biosciences INC (NASDAQ:DTIL) recently purchased 1,682 shares of common stock, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at prices ranging from $4.1…
Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%
[Woman pip petting cells in a laboratory] Unaihuiziphotography/iStock via Getty Images Precision BioSciences (NASDAQ:DTIL [https://seekingalpha.com/symbol/DTIL]) announced [https://seekingalpha.com/pr/20147130-precision-biosciences-receive…
Sidoti Events, LLC's Virtual May Micro-Cap Conference
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, Ma…
7 Biotech Stocks to Buy for Their Game-Changing Potential
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one. Last year, the ecosystem reached a valuation of $1.55 trillion. Between…
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
- Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments - Upfront Cash and Near-Term Payments Expected to Extend Precision’s Cash Runway into the…
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
TG Therapeutics, Inc. US IND filing targeted for mid-2024 NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), “the Company,” today announced that it has entered into an agreement with Precision BioSciences, In…
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
- OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study DURHAM, N.C., December 13, 2023--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an adv…
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
- Publication validates unique ability of ARCUS genome editing to preferentially target and eliminate mutant m.3243G mitochondrial DNA (mtDNA) with high specificity - mitoARCUS efficiently shifted m.3243A>G heteroplasmy without off-target…
Precision BioSciences to Present at Hep-DART 2023
DURHAM, N.C., November 30, 2023--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene…
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., November 28, 2023--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene…
Market Today: Tech Giants and Biotech Suffer Amid Market Retreat
The stock market experienced a downturn as major indices closed in the red. The technology sector, in particular, felt the pressure with semiconductor stocks taking a hit after Analog Devices (NASDAQ:ADI) reported a decline in revenue and…
Market Today: CRISPR Therapeutics and Vertex Pharmaceuticals Make History with UK Drug Approval
The gene editing sector experienced a significant shakeup as CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) received UK approval for their groundbreaking CRISPR-based drug exa-cel, designed to treat sickle cell…
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursda…
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
- PBGENE-HBV designed to both eliminate cccDNA and inactivate HBV DNA - Data demonstrates strong proof of concept efficacy including up to 99% viral engagement and no detectable off-target editing at maximal on-target editing dose - PBGENE…
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Precision BioSciences, Inc. (NASDAQ: DTIL) and Encourages Investors to Contact the Firm
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Precision BioSciences, Inc. (NASDAQ: DTIL) (“Precision”) on behalf of the company’s investors. Since November 2022, shares of Precision’s co…
Precision BioSciences to Present at Upcoming Sidoti Conference
DURHAM, N.C., November 10, 2023--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene…
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Company to Host Webcast and Conference Call on Monday, November 13, 2023 at 4:30 PM ET DURHAM, N.C., November 09, 2023--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel propr…
Precision BioSciences Inc (DTIL) Reports Q3 2023 Financial Results
Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $(0.07) per share, including $4.0 million income from discontinued operations. The company complete…
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023 - Hosted R&D Day highlighting exclusive focus on in vivo gene editing pipeline - Expanded portfolio with PBGENE-PMM as a potentially curativ…